Is Lorazepam a treatment for neuroleptic malignant syndrome?

CNS Spectrums
Andrew FrancisG Petrides

Abstract

The authors assessed the ability of lorazepam and other benzodiazepines to affect the course of neuroleptic malignant syndrome (NMS). Records of inpatients who met both stringent research criteria and criteria under the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, (DSM-IV) (n=11) or DSM-IV criteria alone (n=5) for NMS were identified. All received lorazepam or related benzodiazepines within 24 hours of NMS onset or hospital admission. The records were reviewed for resolution of clinical signs of NMS. Rigidity and fever abated within 24-48 hours, while secondary features of NMS were relieved within 64 hours. These results compared favorably with prior reports of 5-day to 10-day recovery periods. Benzodiazepine administration appeared to be well tolerated. Lorazepam and related benzodiazepines may reduce recovery time in NMS.

References

Oct 1, 1992·The British Journal of Psychiatry : the Journal of Mental Science·D A White
Nov 1, 1991·The British Journal of Psychiatry : the Journal of Mental Science·P I RosebushM F Mazurek
Jun 1, 1989·The American Journal of Psychiatry·P Rosebush, T Stewart
Dec 1, 1989·Biological Psychiatry·G Fricchione
Oct 1, 1985·The American Journal of Psychiatry·J L Levenson
Apr 1, 1986·Acta Psychiatrica Scandinavica·A Shalev, H Munitz
Aug 1, 1987·Biological Psychiatry·G AddonizioS D Roth
Sep 1, 1988·Acta Psychiatrica Scandinavica·V P KontaxakisB J Havaki-Kontaxaki
Jan 1, 1984·Clinical Neuropharmacology·R KurlanI Shoulson
Jan 1, 1993·The Medical Clinics of North America·S N Caroff, S C Mann
Jun 1, 1997·Journal of Clinical Psychopharmacology·B T Carroll, R E Taylor
Nov 14, 1997·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·L C Holloman, S R Marder
Jan 26, 2000·Comprehensive Psychiatry·M KochA Francis

❮ Previous
Next ❯

Citations

Aug 31, 2001·The Journal of ECT·C Malur, A Francis
Jan 1, 2011·The Neurohospitalist·Brian D Berman
May 21, 2013·The Psychiatric Quarterly·Mark B DetweilerJonna G Detweiler
Aug 2, 2002·Clinical Neuropharmacology·Ronald J Gurrera
Apr 27, 2010·Psychiatry and Clinical Neurosciences·Umit Tural, Emin Onder
Apr 29, 2010·Current Psychiatry Reports·Andrew Francis
Feb 19, 2020·International Review of Psychiatry·Charles Mormando, Andrew Francis
Jun 1, 2006·Neuropsychiatric Disease and Treatment·Adeeb Yacoub, Andrew Francis
Jan 26, 2005·International Journal of Psychiatry in Medicine·Mayur Pandya, Leopoldo Pozuelo
Jul 27, 2021·Curēus·Saral DesaiAdela Gerolemou
Aug 15, 2021·Neuropsychopharmacology Reports·UNKNOWN Japanese Society of Neuropsychopharmacology

❮ Previous
Next ❯

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.